ArticleFrontiers in immunology2025
Clinical characteristics, prognosis, and predictive modeling in class IV ± V lupus nephritis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Spectrum of biopsy-proven kidney diseases in 3514 patients at a single center in Northwest China from 2014 to 2023.Clinical and experimental nephrology · 2026Article
- Serum RNASE1 as a biomarker for disease activity and lupus nephritis in systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Identifying gut microbiotaFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study is to compare the clinical features and survival outcomes of class IV ± V lupus nephritis (LN) patients, identify risk factors, and develop an accurate prognostic model. Methods: This study enrolled patients diagnosed with class IV ± V LN by renal biopsy at Xijing Hospital from December 2013 to June 2023. The composite endpoint of the study was defined as a decline in the estimated glomerular filtration rate (eGFR) by more than 50%, progression to end stage renal disease, or death, whichever came first. The eGFR was calculated utilizing the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. ESRD is defined as an eGFR less than 15ml/min/1.73m Results: A total of 313 patients were enrolled for this study, including 156 class IV and 157 class IV+V LN. During the median follow-up period of 42.6 (17.0, 83.4) months, 35 (22.4%) class IV and 38 (24.2%) class IV+V LN patients experienced combined events. Class IV and class IV+V patients have similar clinical manifestations, treatment strategies, and long-term prognosis, despite class IV having a higher chronic index (CI) score ( Conclusion: Class IV ± V LN was similar in clinical manifestations, treatment strategies, and long-term prognosis, despite differences in pathological features. The RSF model we established for class IV ± V LN patients, incorporating seven risk factors, exhibits superior survival prediction and provides more precise prognostic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.